New cancer clinical trial: A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

Published on: November 30, 2018 at 12:00PM
Conditions:   Incurable Platinum Refractory Germ Cell Tumors;   Tumors
Intervention:   Drug: ASP1650
Sponsor:   Astellas Pharma Global Development, Inc.
Not yet recruiting
https://ift.tt/2DUfNMq